MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, BCAX had -$264,933K decrease in cash & cash equivalents over the period. -$29,290K in free cash flow.

Cash Flow Overview

Change in Cash
-$264,933K
Free Cash flow
-$29,290K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-36,330 -64,234
Stock-based compensation
3,614 6,943
Depreciation
24 38
Non-cash lease expense
249 349
Net amortization of premiums and discounts on investments
-32 -
Prepaid expenses and other assets
301 -4,743
Accounts payable and accrued expenses-Nonrelated Party
3,949 -2,715
Accounts payable and accrued expenses-Related Party
-168 1,499
Operating lease liabilities
-317 -323
Net cash used in operating activities
-29,248 -53,700
Purchases of investments
236,079 -
Purchase of property and equipment
42 0
Proceeds from sale of property and equipment
0 0
Net cash (used in)/provided by investing activities
-236,121 0
Proceeds from issuance on common stock, net of issuance costs
0 -
Proceeds from exercise of options
436 595
Payment for deferred offering costs
-0
Net cash provided by financing activities
436 595
Net (decrease)/increase in cash and cash equivalents
-264,933 -53,105
Cash and cash equivalents at beginning of period
489,711 -
Cash and cash equivalents at end of period
171,673 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Inc. (BCAX)